Lipitor keeps on selling, so Pfizer will keep on producing it in Ireland

It's official: Demand for the off-patent drug Lipitor has inspired Pfizer ($PFE) to keep an Irish plant it had slated for closure. Sales in emerging markets, and to a lesser extent the U.S., are behind the change of mind, which saves 160 jobs in Little Island, Cork. Improved productivity at the plant helped, too. Release | More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?